Drugs / TAB006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05253105 | Mar 2022 → Sep 2026 | cancer | Shanghai Junshi Bioscience Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAB006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05253105 ↗ |
| Modality | Monoclonal antibody | “TAB006 is a recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb)” NCT05253105 ↗ |
| Route | Intravenous | “TAB006 is administered as an intravenous infusion (IV) over 60 minutes” NCT05253105 ↗ |